Construction and immunological study of recombinant hBD-2/PSMA chimeric protein eukaryotic expressive plasmid.
- Author:
Ming LI
1
;
Yan SUN
;
Yun FENG
;
Qi WU
;
Ning HUANG
;
Boyao WANG
Author Information
1. Research Institute of Infection and Immunity, West China Medical Center of Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
3T3 Cells;
Animals;
Eukaryotic Cells;
metabolism;
Genetic Vectors;
Humans;
Immunotherapy, Active;
Male;
Mice;
Mice, Inbred BALB C;
Plasmids;
immunology;
Prostate-Specific Antigen;
genetics;
immunology;
Prostatic Neoplasms;
immunology;
pathology;
therapy;
Recombinant Fusion Proteins;
immunology;
T-Lymphocytes, Cytotoxic;
immunology;
Transfection;
Tumor Cells, Cultured;
Vaccines, DNA;
genetics;
immunology;
beta-Defensins;
genetics;
immunology
- From:
Journal of Biomedical Engineering
2005;22(2):283-287
- CountryChina
- Language:Chinese
-
Abstract:
The recombinant PSMA DNA vaccine for active immunotherapy of prostate cancer was investigated. Two DNA vaccine recombinant plasmids, pcDNA3.1/PSMA and pcDNA3.1/hBD-2-PSMA, were constructed by inserting the hBD-2 gene and PSMA gene into an eukarytoic expression vector pcDNA3.1. Expression of the two recombinants was detected in transfected COS-7 cells and inoculated mouse muscular cells by RT-PCR and immunohistochemical method. When immunized with pcDNA3.1/PSMA and pcDNA3.1/hBD-2-PSMA, the immunized BALB/c mice acquired specific antibody and T cell response to PSMA. The quantity of the spleen lymphocytes and their CTL activity against PSMA gene transfected-BALB/3T3 cells significantly increased in the immunized mice, and the CTL activity of lymphocytes from pcDNA3.1/hBD-2-PSMA immunized mice was significantly higher than that of pcDNA3.1/PSMA immunized mice. This result suggests that pcDNA3.1/hBD-2-PSMA would probably be developed as a DNA vaccine for the immunotherapy of prostate cancer.
